During the past decade, Charite-Campus Benjamin Franklin conducted 114 clinical trials. In the 10-year time frame, 114 clinical trials started and 47 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 53 clinical trials started and 28 clinical trials were completed. i.e. 52.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Charite-Campus Benjamin Franklin" #1 sponsor was "Charite University, Berlin, Germany" with 30 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 13 trials sponsored, "Pfizer" with 13 trials sponsored, "Celgene" with 12 trials sponsored and "Abbott Medical Devices" with 12 trials sponsored. Other sponsors include 146 different institutions and companies that sponsored additional 103 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Charite-Campus Benjamin Franklin" #1 collaborator was "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" with 6 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator, "Bayer" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator and "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials as a collaborator. Other collaborators include 110 different institutions and companies that were collaborators in the rest 107 trials.

According to Clinical.Site data, the most researched conditions in "Charite-Campus Benjamin Franklin" are "Crohn's Disease" (10 trials), "Acute Myeloid Leukemia" (9 trials), "Ulcerative Colitis" (9 trials), "Atrial Fibrillation" (8 trials) and "Coronary Artery Disease" (8 trials). Many other conditions were trialed in "Charite-Campus Benjamin Franklin" in a lesser frequency.

Most popular intervention types in "Charite-Campus Benjamin Franklin" are "Drug" (152 trials), "Device" (37 trials), "Biological" (27 trials), "Other" (20 trials) and "Procedure" (20 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (32 trials), "Dexamethasone" (7 trials), "Rituximab" (7 trials), "cyclophosphamide" (7 trials) and "Blinatumomab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Charite-Campus Benjamin Franklin" are 219 trials for "All" genders, 6 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Charite-Campus Benjamin Franklin". undefined are not yet recruiting, 39 are recruiting, 23 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 120 completed trials in Charite-Campus Benjamin Franklin, undefined suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in Charite-Campus Benjamin Franklin, 12 "Phase 1" clinical trials were conducted, 70 "Phase 2" clinical trials and 81 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 36 trials that are defined as “Not Applicable".